论文部分内容阅读
乳腺癌是妇女中最常见的恶性疾病。目前最有希望的是化疗。晚期乳腺癌用多种化疗制剂比单用一种更有效;但在早期乳腺癌中,副作用较大,是否能对抗微转移尚属疑问;再则,化疗特别是用多种有力制剂的远期效果如何尚不明。患早期乳腺癌伴组织学阳性淋巴结的妇女愈后差。早期乳腺癌伴组织学阴性淋巴结的妇女,其中3/4在5年时生存,2/3在10年时生存。对较进展的乳腺癌患者,要等到化疗方案被证明是安全而有效时,再行治疗或许是明智的。Fisher 等最近报道,在乳房根治术后,患早期癌伴组织学阳性淋巴结的妇女接受了化疗,无病间隔期延长(经
Breast cancer is the most common malignant disease in women. The most promising currently is chemotherapy. The use of multiple chemotherapy formulations for advanced breast cancer is more effective than single use; but in early breast cancer, side effects are greater, and it is questionable whether it can combat micrometastases; in addition, the long-term use of chemotherapy, especially with a variety of potent agents The effect is still unknown. Women with early-stage breast cancer with histologically positive lymph nodes are worse off. Of the women with early breast cancer and histologically negative lymph nodes, 3/4 survived at 5 years and 2/3 survived at 10 years. For more advanced breast cancer patients, it may be wise to wait until the chemotherapy regimen proves to be safe and effective. Fisher et al. recently reported that after radical mastectomy, women with early-stage cancer associated with histologically positive lymph nodes undergo chemotherapy and prolong the disease-free interval.